Moleculin Biotech target adjusted to $8 from $45 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Moleculin Biotech (MBRX) to $8 from $45 and keeps a Buy rating on the shares. The firm adjusted its model to the effect of a 1-for-15 reverse stock split that took effect in March 2024.